Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old

Fitzpatrick, David; Young, Mariano; Yacisin, Kari; McElwee, Kathleen; Belanger, Todd; Belanger, Kelly A.; Peng, Yahong; Lee, Dung-Yang; Gruber, William C.; Scott, Daniel A.; Watson, Wendy

doi:10.1016/j.vaccine.2023.05.002

Cited by 6 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 40 To protect individuals from VOCs, booster doses of the COVID-19 vaccine have been recommended in many countries, and one potential strategy to promote COVID-19 booster is vaccine coadministration. 41 It has been shown that vaccine coadministration is effective and more cost-effective than programs aiming at promoting one vaccine alone. One systematic review of the coadministration of seasonal influenza and COVID-19 vaccines showed that the coadministration of these two vaccines is safe and does not have immunological interference.…”

Section: Discussionmentioning

confidence: 99%

Vaccination status and disease severity of COVID-19 in different phases of the pandemic

Yang,

Shi,

Zhang

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Vaccination status and disease severity of COVID-19 in different phases of the pandemic

Yang,

Shi,

Zhang

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…The results suggested that the neutralizing titers against SARS-CoV-2 virus and the S-binding IgG titers were similar in the co-administration group and the BNT162b2-only group. Similarly, the immunogenicity of PCV20 was comparable, showing noninferiority if it was co-administered, as compared to participants receiving PCV20 only [ 74 ].…”

Section: Pneumococcal Vaccinationmentioning

confidence: 99%

Bacterial Vaccinations in Patients with Chronic Obstructive Pulmonary Disease

Paróczai,

Burian,

Bikov

2024

Vaccines

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a frequent, often progressive, chronic disease of the lungs. Patients with COPD often have impaired immunity; therefore, they are prone to chest infections, such as pneumonia or bronchitis. Acute exacerbations of COPD are major events that accelerate disease progression, contributing to its symptoms’ burden, morbidity, and mortality. Both pneumonia and acute exacerbations in COPD are caused by bacteria against which there are effective vaccinations. Although the number of randomised controlled studies on bacterial vaccinations in COPD is limited, national and international guidelines endorse specific vaccinations in patients with COPD. This review will summarise the different types of vaccinations that prevent pneumonia and COPD exacerbations. We also discuss the results of early phase studies. We will mainly focus on Streptococcus pneumoniae, as this bacterium was predominantly investigated in COPD. However, we also review studies investigating vaccinations against Haemophilus influenzae, Moraxella catarrhalis, and Bordetella pertussis.

show abstract